RxDoctor Payments Data

Malathy Tharumarajah, MD

Internal Medicine · Penfield, NYNPI 1982011615

Payments from drug & device makers

$1,571in general payments, 2019–2025

Across 95 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$494
  • Lilly USA, LLC$340
  • AstraZeneca$201
  • Sanofi-aventis U.S. LLC$163
  • Boehringer Ingelheim$157
  • Amgen$55
  • plus $160 from 8 others

What the payments were for

  • Food & beverage$1,54198%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,571 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$21,482
Medicare patients
87
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$49,037
JardianceEmpagliflozin49$46,743
MounjaroTirzepatide34$37,282
OzempicSemaglutide31$30,426
XareltoRivaroxaban28$28,752
FarxigaDapagliflozin Propanediol14$18,106
JanuviaSitagliptin Phosphate20$16,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,392
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$7,214
Repatha SureclickEvolocumab11$6,921
Atorvastatin Calcium411$5,726
Praluent PenAlirocumab12$5,687
DuleraMometasone/Formoterol13$5,425
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,370
Arnuity ElliptaFluticasone Furoate15$4,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$49,03750 claims
Boehringer IngelheimJardiance$157$46,74349 claims
Lilly USA, LLCMounjaro$340$37,28234 claims
Novo NordiskOzempic$494$30,42631 claims
MerckJanuvia, Dulera$32$22,40033 claims
AstraZenecaFarxiga$201$18,10614 claims
AbbVieSynthroid$16$1,85927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Penfield

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →